References
- Matlock A, Allan N, Wills B, Kang C, Leikin JB. A continuing black hole? The FDA boxed warning: An appeal to improve its clinical utility. Clin Toxicol 2011; 49:443–447.
- Borg JJ, Aislaitner G, Pirozynski M, Mifsud S. Strengthening and rationalizing pharmacovigilance in the EU: where is Europe heading to? A review of the new EU legislation on pharmacovigilance. Drug Saf 2011; 34:187–197.
- Wall AJ, Bateman DN, Waring WS. Variability in the quality of overdose advice in summary of product characteristics (SPC) documents: gut decontamination recommendations for CNS drugs. Br J Clin Pharmacol 2009; 67:83–87.
- Mallows J, Chan B, Graudins A. Quality of poisoning management advice in the Monthly Index of Medical Specialties Annual. Emerg Med Australas 2005; 17:511–519.
- McLernon DJ, Bond CM, Hannaford PC, Watson MC, Lee AJ, Hazell L, Avery A. Yellow Card Collaboration. Adverse drug reaction reporting in the United Kingdom: a retrospective observational comparison of yellow card reports submitted by patients and healthcare professionals. Drug Saf 2010; 33:775–788.
- Kendall M. Chairman of the Joint Formulary Committee, British National Formulary. Clin Med 2009; 9:349–352.
- Heeley E, Riley J, Layton D, Wilton LV, Shakir SA. Prescription-event monitoring and reporting of adverse drug reactions. Lancet 2001; 358:1872–1873.
- Swain E, Morgan S, Brewster W, Kauser S. Early communication of drug safety concerns: a feasibility study on enhancing interaction between the pharmaceutical industry and regulators. Pharmacoepidemiol Drug Saf 2010; 19:232–237.
- Breckenridge A. The future of drug safety. Clin Pharmacol Ther 2007; 81:161–163.
- Thanacoody HK, Good AM, Waring WS, Bateman DN. Survey of cases of paracetamol overdose in the United Kingdom referred to National Poisons Information Service (NPIS) consultants. Emerg Med J 2008; 25:140–143.
- Waring WS, Palmer SR, Bateman DN. Alerting and surveillance using poisons information systems (ASPIS): outcomes from an international working group. Clin Toxicol 2007; 45:543–548.
- MHRA. Immediate withdrawal of rofecoxib (Vioxx/Vioxxacutate). 30 September 2004. http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON1004263">. Accessed 20 April 2011.
- MHRA. Advice for patients following the withdrawal of a widely-used painkiller/anti-inflammatory: Vioxx. 30 September 2004. http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON002056. Accessed 20 April 2011.
- MHRA. MHRA issues updated advice on the safety of selective Cox-2 inhibitors. 17 Feb 2005. http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarnings andmessagesformedicines/CON1004250. Accessed 20 April 2011.
- European Medicines Agency. Public CHMP assessment report for medicinal products containing non-selective nonsteroidal anti-inflammatory drugs (NSAIDs). 7 November 2006. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2010/01/WC500054344.pdf. Accessed 20 April 2011.
- NHS Prescription Service. NSAIDs and analgesic national charts. June 2010. www.nhsbsa.nhs.uk/PrescriptionServices/Documents/PPDPrescribingAnalysisCharts/NSAIDs_National_June_10.pdf. Accessed 20 April 2011.
- MHRA. Cardiovascular safety of Cox-2 inhibitors and non-selective NSAIDs. Public Assessment Report. http://www.mhra.gov.uk/Safetyinformation/Generalsafetyinformationandadvice/Product-specific informationandadvice/Product-specificinformationandadvice-A-F/ CardiovascularsafetyofCOX-2inhibitorsandnon-selectiveNSAIDs/index.htm. Accessed 20 April 2011.
- Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giffin SL. 2009 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 27th Annual Report. Clin Toxicol (Phila) 2010; 48:979–1178.
- Buckley NA, Whyte IM, Dawson AH. Cardiotoxicity more common in thioridazine overdose than with other neuroleptics. J Toxicol Clin Toxicol 1995; 33:199–204.
- Poon H, Elliot V, Bateman DN, Waring WS. Impact of legislative changes on patterns of antipsychotic prescribing and self-poisoning in Scotland: 2000–06. J Toxicol Sci 2007; 32:1–7.
- MHRA. New advice issued on risperidone and olanzapine. September 2005. http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/CON002047. Accessed 20 April 2011.
- NHS Prescription Service. Central nervous system national charts. April 2010. http://www.nhsbsa.nhs.uk/PrescriptionServices/Documents/PPDPrescribingAnalysisCharts/NPC_Maps_CNS_April_2010.pdf - 208KB. Accessed 20 April 2011.
- Doak MW, Nixon AC, Lupton DJ, Waring WS. Self-poisoning in older adults: patterns of drug ingestion and clinical outcomes. Age and Ageing 2009; 38:407–411.
- Nickander RC, Emmerson JL, Hynes MD, Steinberg MI, Sullivan HR. Pharmacologic and toxic effects in animals of dextropropoxyphene and its major metabolite norpropoxyphene: a review. Hum Toxicol 1984; 3(Suppl):13S–36S.
- Hawton K, Simkin S, Deeks J. Co-proxamol and suicide: a study of national mortality statistics and local non-fatal self poisonings. BMJ 2003; 326:1006–1008.
- MHRA. Prescription trends in analgesics 2003–2008: before, during and after the withdrawal of co-proxamol. http://www.mhra.gov.uk/home/groups/es-foi/documents/foidisclosure/con100023.pdf. Accessed 20 April 2011.
- Corcoran P, Reulbach U, Keeley HS, Perry IJ, Hawton K, Arensman E. Use of analgesics in intentional drug overdose presentations to hospital before and after the withdrawal of distalgesic from the Irish market. BMC Clin Pharmacol 2010; 10:6.
- Sandlands EA, Bateman DN. Co-proxamol withdrawal has reduced suicide from drugs in Scotland. Br J Clin Pharmacol 2008; 66: 290–293.
- Watson WA, Litovitz TL, Belson MG, Wolkin AB, Patel M, Schier JG, . The toxic exposure surveillance system (TESS): risk assessment and real-time toxicovigilance across United States poison centers. Toxicol Appl Pharmacol 2005; 207(2 Suppl): 604–610.